Infection prevention & Control Market by Accessories and Equipment 2020 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Infection prevention & control market
Infection prevention & Control Market: By Infections (Microbial and Others) By Antimicrobial Drugs (Antibacterial & Others) By Accessories and Equipment (Disinfectants and Others) By End User (Equipment & Drug Usage) & By Geography-Forecast(2015-2020)
Report Code : HCR 0022
Published: 06 January, 2015   No. of pages: 180

  • Report Description
  • Table of Contents
  • Tables And Figures
  • Customization Options
Infection prevention and Control (IPC) is a rapidly growing field in the healthcare industry. The proper usage of the IPC products all across the globe has the potential to revolutionize the complete healthcare industry, making it disease free. The market opportunity for IPC is promising, yet conflicting financial Incentives has created uncertainty on how stakeholders can capitalize. The market for Infection prevention is estimated to increase with a CAGR of 5.3% during the forecast period 2015-2020. Infection prevention and control market is experiencing significant growth with the increase in awareness among the people, elderly & aging population, and number of surgeries and proper donning and doffing of Hospital Housekeeper which prevents in the spread of the contagious waste.

Infection prevention and control is the major and significant step in the development and maintenance of products in the Medical Devices, Pharmaceuticals, and food & beverage industries. The adoption of various means of personal protective equipment, disinfection, sterilization and in-house sterilization procedures by hospitals and end users industries has revolutionized the healthcare industry. Sterilization and disinfection protect different products and materials from being contaminated by microbes. The disinfection and sterilization market is going to expand with a CAGR of 6.2% during the period under study. The integration of technologies into traditional healthcare systems is one of the most influencing trends that will drive the growth of the infection prevention and control market. The technological advancements will facilitate the availability and implementation of cost-effective technologies across a range of healthcare facilities. The introduction of technically enhanced instruments likes portable autoclaves, In-House & ethylene oxide (EtO) advanced sterilization and so on has resulted in the drastic swing from the previous used equipment’s such as steam sterilizer.

The IPC market by anti-microbial drugs in North America in 2014 was valued at $XX billion and is projected to grow at a CAGR of 4.5% during the forecast period. The North American region has been concentrating on relatively easy commercial drugs which were driven by the increase in chronic diseases. This has led to the development of vaccines, since these are specific for a particular infection. The cost of the vaccines varies as per the infected microbes. Thus, followed by anti-bacterial drugs, vaccines show the highest growth rate of 4.8% towards the increasing demand of anti-microbial drugs, where most patients would be managed with a short course of therapy in comparison to the generic antibiotics. According to the World Health Organization, 30.85% of the globally registered hospitals are in the Americas. Moreover, the rapidly aging population in the U.S., Canada and Mexico will drive the need for efficient anti-microbial drugs in hospitals and senior care centres in this region.

The global infection prevention and control market is segmented into bacterial, fungal and viral infections based on the types of microbial infections. In 2014, bacterial infections dominated the market with 44% of the global market share in infection prevention and control market, followed by viral infections, which occupied 39%.
1. Global Infection Prevention & Control Market Overview
2. Global Infection Prevention & Control Market - Executive Summary
3. Infection Prevention & Control Market Landscape
   3.1. Market share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End-User Profiling
      3.2.3. Patent Analysis
      3.2.4. Top 5 Financial Analysis
4. Infection Prevention & Control Market Forces
   4.1. Market Drivers
   4.2. Market Constraints
   4.3. Market Challenges
   4.4. Attractiveness of the Industry
      4.4.1. Power of Suppliers
      4.4.2. Power of Customers
      4.4.3. Threat of New entrants
      4.4.4. Threat of Substitution
      4.4.5. Degree of Competition
5. Infection Prevention & Control Market – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Opportunity Analysis
   5.3. Product Life Cycle Analysis
   5.4. Pricing Analysis
6. Infection Prevention & Control Market – By Infections
   6.1. Microbial Infections
      6.1.1. Bacterial Infection
            6.1.1.1. Mycobacterium tuberculosis
            6.1.1.2. Clostridium Difficile
            6.1.1.3. E. Coli
            6.1.1.4. Helicobacter pylori
            6.1.1.5. Salmonella
            6.1.1.6. Others
      6.1.2. Viral Infection
            6.1.2.1. Ebola Virus
            6.1.2.2. Human Immunodeficiency Virus (HIV)
            6.1.2.3. Herpes Simplex Virus
            6.1.2.4. Yellow Fever
            6.1.2.5. Dengue Viruses
            6.1.2.6. Others
      6.1.3. Fungal Infection
            6.1.3.1. Cryptococcus gattii
            6.1.3.2. Aspergillis
            6.1.3.3. PCP: Pneumocystis Pneumonia
            6.1.3.4. Fungal Keratitis
            6.1.3.5. Dermatophytes
            6.1.3.6. Others
   6.2. Healthcare Associated Infection
      6.2.1. Hospital Acquired Infection
            6.2.1.1. Central Line-associated Bloodstream Infection (CLABSI)
            6.2.1.2. Catheter-associated Urinary Tract Infection
            6.2.1.3. Surgical Site Infection
            6.2.1.4. Ventilator-associated Pneumonia (VAP) Infection
      6.2.2. Community acquired Infection
            6.2.2.1. Methicillin-resistant Staphylococcus aureus (MRSA) infection
            6.2.2.2. Community-acquired pneumonia
7. Infection Prevention & Control Market - By Anti-Microbial Drugs
   7.1. Anti- Bacterial Drugs
   7.2. Anti- Viral Drugs
   7.3. Anti-fungal Drugs
   7.4. Vaccines
8. Prevention & Control Market - By Accessories and Equipment
   8.1. Personal Protective Equipment
      8.1.1. Gloves
      8.1.2. Surgical Masks & Respirators
      8.1.3. Surgical Drapes & Gown
      8.1.4. Surgical Foot Covers
      8.1.5. Medical Safety Glasses
      8.1.6. Others
   8.2. Disinfectants
      8.2.1. Hand Sanitizers
      8.2.2. Disinfectant Wipes
      8.2.3. Surface Disinfectants
      8.2.4. Instrument Disinfectants
      8.2.5. Surgical Disinfectants
      8.2.6. Environmental Disinfectants
      8.2.7. Others
   8.3. Sterilization
      8.3.1. Medical Device Sterilization Equipment
            8.3.1.1. Wet/ Steam Sterilization (Autoclave)
                     8.3.1.1.1. Vertical Autoclave
                     8.3.1.1.2. Horizontal Autoclave
                     8.3.1.1.3. Portable Autoclave
            8.3.1.2. Dry Heat Sterilization
            8.3.1.3. Low Temperature Sterilization
                     8.3.1.3.1. In-House Steam Sterilization
                     8.3.1.3.2. Ethylene Oxide (EO) Sterilization
                     8.3.1.3.3. Gamma and eBeam Sterilization
9. Infection Prevention & Control Market - By End User Industry
   9.1. End Users: By Equipment Usage
      9.1.1. Hospitals & Clinics
      9.1.2. Medical laboratories
      9.1.3. Manufacturing Units
            9.1.3.1. Pharmaceuticals
            9.1.3.2. Medical Devices
            9.1.3.3. Food & Beverages Industry
   9.2. End Users: By Drug Usage
      9.2.1. Individuals & Patients
      9.2.2. Nursing & Senior care Centers
10. Infection Prevention & Control Market – Regulatory Scenario
11. Infection Prevention & Control Market - Geographic Analysis
   11.1. Introduction 
   11.2. North America
      11.2.1. US
      11.2.2. Canada
      11.2.3. Mexico
      11.2.4. Others
   11.3. Europe
      11.3.1. France
      11.3.2. Germany
      11.3.3. Italy
      11.3.4. Spain
      11.3.5. UK
      11.3.6. Others
   11.4. APAC
      11.4.1. China
      11.4.2. India
      11.4.3. Japan
      11.4.4. Korea
      11.4.5. Others 
   11.5. ROW
      11.5.1. Saudi Arabia
      11.5.2. South Africa
      11.5.3. Brazil
      11.5.4. Russia
      11.5.5. Others
12. Infection prevention and Control Market Entropy
   12.1. New Product Launches
   12.2. M&As, Collaborations, JVs and Partnerships
13. Infection prevention and Control Market Company Profiles (Overview, Financials, SWOT Analysis – Top 5 Companies, Developments, Product Portfolios)  
   13.1. ABBOTT LABORATORIES (ABBOTT DIACNOSTICS)
   13.2. ALERE
   13.3. ANSELL LIMITED
   13.4. ASTRAZENECEA
   13.5. BARD (CR) INCORPORATED
   13.6. BECTON, DICKINSON AND COMPANY
   13.7. BELIMED
   13.8. CANTEL
   13.9. COVIDIEN PLC
   13.10. GETINGE GROUP
   13.11. HOLLISTER INCORPORATED
   13.12. JOHNSON & JOHNSON
   13.13. KIMBERLY-CLARK
   13.14. MERCK & CO
   13.15. PFIZER
   13.16. ROCHE
   13.17. SIEMENS AG
   13.18. SUPERMAX CORPORATION
   13.19. TERUMO CORPORATION
   13.20. 3M COMPANY
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
14. Appendix
   14.1. Abbreviations
   14.2. Sources
   14.3. Research Methodology
   14.4. Bibliography
   14.5. Compilation of Expert Insights
   14.6. Disclaimer
List of Tables:

Table 1. Global IP&C Market Key Players, Market Shares By Revenue 2013 (%)
Table 2. Product Benchmarking for Surgical N95 Mask – By Pricing
Table 3. Product Benchmarking for Anti-Bacterial Drugs: By Key Players
Table 4. Key Patents By IP&C Player In 2014
Table 5. Top Five Financial Analysis for IP&C Market 2013 ($Million)
Table 6. Cost of Surgical Procedures (In $): By Disease Indication
Table 7. Population above 65 Years of Age, By Region (Millions)
Table 8. Top Company’s Patent Cliff Analysis (Patent Expiry 2014)
Table 9. List of Drug-Resistant Infectious Agents; By Country/ Region (%)
Table 10. U.S. Statistics of Drug Resistant Tuberculosis In 2013
Table 11. List of Few Common Human Viruses Associated With Cancer
Table 12. Global IP&C Anti Microbial Drugs Market, By Microbial Infections, 2013-2020 ($Billion)
Table 13. North America IP&C Anti Microbial Drugs Market, By Microbial Infections, 2013-2020 ($Billion)
Table 14. Europe IP&C Anti Microbial Drugs Market, By Microbial Infections, 2013-2020 ($Billion)
Table 15. IP&C Anti Microbial Drugs Market, By Microbial Infections, 2013-2020 ($Billion)
Table 16. Row IP&C Anti Microbial Drugs Market, By Microbial Infections, 2013-2020 ($Billion)
Table 17. Economics Cost Associated With Hospital-Acquired Infection
Table 18. Rate of the Infection WRT Device-Associated Infections
Table 19. Global IP&C Accessories & Equipment Market, By Hai, 2013-2020 ($Billion)
Table 20. North America IP&C Accessories & Equipment Market, By Hai, 2013-2020 ($Billion)
Table 21. Europe IP&C Accessories & Equipment Market, By Hai, 2013-2020 ($Billion)
Table 22. APAC IP&C Accessories & Equipment Market, By Hai, 2013-2020 ($Billion)
Table 23. Row IP&C Accessories & Equipment Market, By Hai, 2013-2020 ($Billion)
Table 24. List of Recently Approved Anti- Bacterial Drugs (2000-2014)
Table 25. List of Approved Antiviral Drugs
Table 26. List of Approved Anti- Fungal Drugs
Table 27. List of Approved Preventive Vaccines
Table 28. Global IP&C Market, By Antimicrobial Drugs, 2013-2020 ($Billion)
Table 29. North America IP&C Market, By Antimicrobial Drugs, 2013-2020 ($Billion)
Table 30. Europe IP&C Market, By Antimicrobial Drugs, 2013-2020 ($Billion)
Table 31. APAC IP&C Market, By Antimicrobial Drugs, 2013-2020 ($Billion)
Table 32. Row IP&C Market, By Antimicrobial Drugs, 2013-2020 ($Billion)
Table 33. Global IP&C Market, By Types of PPE, 2013-2020 ($Billion)
Table 34. North America IP&C Market, By Types of PPE, 2013-2020 ($Billion)
Table 35. Europe IP&C Market, By Types of PPE, 2013-2020 ($Billion)
Table 36. APAC IP&C Market, By Types of PPE, 2013-2020 ($Billion)
Table 37. Row IP&C Market, By Types of PPE, 2013-2020 ($Billion)
Table 38. Frequency of Hand Washing & Its Co-Relation In Infection Prevention
Table 39. Global IP&C Market, By Types of Disinfectants, 2013-2020 ($Billion)
Table 40. North America IP&C Market, By Types of Disinfectants, 2013-2020 ($Billion)
Table 41. Europe IP&C Market, By Types of Disinfectants, 2013-2020 ($Billion)
Table 42. APAC IP&C Market, By Types of Disinfectants, 2013-2020 ($Billion)
Table 43. Row IP&C Market, By Types of Disinfectants, 2013-2020 ($Billion)
Table 44. Global IP&C Market, By Types of Sterilization, 2013-2020 ($Billion)
Table 45. North America IP&C Market, By Types of Sterilization, 2013-2020 ($Billion)
Table 46. Europe IP&C Market, By Types of Sterilization, 2013-2020 ($Billion)
Table 47. APAC IP&C Market, By Types of Sterilization, 2013-2020 ($Billion)
Table 48. Row IP&C Market, By Types of Sterilization, 2013-2020 ($Billion)
Table 49. Global IP&C Market, By Types of Autoclave, 2013-2020 ($Million)
Table 50. North America IP&C Market, By Types of Autoclave, 2013-2020 ($Million)
Table 51. Europe IP&C Market, By Types of Autoclave, 2013-2020 ($Million)
Table 52. APAC IP&C Market, By Types of Autoclave, 2013-2020 ($Million)
Table 53. Row IP&C Market, By Types of Autoclave, 2013-2020 ($Million)
Table 54. Global IP&C Market, By Equipments & Accessories End User’s 2013–2020 ($Billion)
Table 55. North America IP&C Market, By Equipments & Accessories End User’s 2013–2020 ($Billion)
Table 56. Europe IP&C Market, By Equipments & Accessories End User’s 2013–2020 ($Billion)
Table 57. APAC IP&C Market, By Equipments & Accessories End User’s 2013–2020 ($Billion)
Table 58. Row IP&C Market, By Equipments & Accessories End User’s 2013–2020 ($Billion)
Table 59. Global IP&C Market, By Anti-Microbial Drugs End User’s 2013–2020 ($Billion)
Table 60. North America IP&C Market, By Anti-Microbial Drugs End User’s 2013–2020 ($Billion)
Table 61. Europe IP&C Market, By Anti-Microbial Drugs End User’s 2013–2020 ($Billion)
Table 62. APAC IP&C Market, By Anti-Microbial Drugs End User’s 2013–2020 ($Billion)
Table 63. Row IP&C Market, By Anti-Microbial Drugs End User’s 2013–2020 ($Billion)
Table 64. Global IP&C Anti Microbial Drug Market, 2013–2020 ($Billion)
Table 65. Global IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 66. North America IP&C Anti Microbial Drug Market, 2013–2020 ($Billion)
Table 67. North America IP&C Accessories & Equipment’s Market 2013– 2020 ($Billion)
Table 68. United States IP&C Market Anti Microbial Drug Market, 2013–2020 ($Billion)
Table 69. United States IP&C Accessories & Equipments Market, 2013–2020 ($Billion)
Table 70. Canada IP&C Anti Microbial Drug Market, 2013–2020 ($Billion)
Table 71. Canada IP&C Accessories & Equipments Market, 2013–2020 ($Billion)
Table 72. Mexico IP&C Anti Microbial Drug Market, 2013–2020 ($Billion)
Table 73. Mexico IP&C Accessories & Equipments Market, 2013–2020 ($Billion)
Table 74. Others IP&C Anti Microbial Drug Market, 2013–2020 ($Billion)
Table 75. Others IP&C Accessories & Equipments Market, 2013–2020 ($Billion)
Table 76. Europe IP&C Anti Microbial Drug Market, 2013–2020 ($Billion)
Table 77. Europe IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 78. U.K. IP&C Anti Microbial Drug Market, 2013–2020 ($Billion)
Table 79. U.K. IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 80. Germany IP&C Anti Microbial Drug Market, 2013–2020 ($Billion)
Table 81. Germany IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 82. Italy IP&C Anti Microbial Drug Market, 2013–2020 ($Billion)
Table 83. Italy IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 84. Spain IP&C Anti Microbial Drug Market, 2013–2020 ($Billion)
Table 85. Spain IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 86. France IP&C Anti Microbial Drug Market, 2013–2020 ($Billion)
Table 87. France IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 88. Others IP&C Anti Microbial Drug Market, 2013–2020 ($Billion))
Table 89. Others IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 90. APAC IP&C Anti Microbial Drug Market, 2013–2020 ($Billion))
Table 91. APAC IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 92. China IP&C Anti Microbial Drug Market, 2013–2020 ($Billion))
Table 93. China IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 94. Japan IP&C Anti Microbial Drug Market, 2013–2020 ($Billion))
Table 95. Japan IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 96. Korea IP&C Anti Microbial Drug Market, 2013–2020 ($Billion))
Table 97. Korea IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 98. India IP&C Anti Microbial Drug Market, 2013–2020 ($Billion))
Table 99. India IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 100. Others IP&C Anti Microbial Drug Market, 2013–2020 ($Billion))
Table 101. Others IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 102. Row IP&C Anti Microbial Drug Market, 2013–2020 ($Billion))
Table 103. Row IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 104. Saudi Arabia IP&C Anti Microbial Drug Market, 2013–2020 ($Billion))
Table 105. Saudi Arabia IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 106. South Africa IP&C Anti Microbial Drug Market, 2013–2020 ($Billion))
Table 107. South Africa IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 108. Brazil IP&C Anti Microbial Drug Market, 2013–2020 ($Billion))
Table 109. Brazil IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 110. Russia IP&C Anti Microbial Drug Market, 2013–2020 ($Billion)
Table 111. Russia IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 112. Others IP&C Anti Microbial Drug Market, 2013–2020 ($Billion))
Table 113. Others IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 114. List of Acquisitions of Global Infection Prevention & Control Market Players
Table 115. List of Product Launches of Global Infection Prevention & Control Market Players
Table 116. List of Collaborations & Strategic Partnerships By Key Players In Global Infection Prevention & Control Market
Table 117. Abbott Revenue, 2013–2020 ($Billion)
Table 118. Alere Inc. Net Revenue - 2011-2013 ($Million)
Table 119. Alere Inc. Net Revenue- By Business Segment, 2010-2013 ($Million)
Table 120. Alere Inc. Net Product Sales and Services Revenue - By Geography Solutions, 2012-2013 ($Million)
Table 121. Ansell Ltd, Total Revenue 2012– 2013 ($Million)
Table 122. Ansell Ltd, Total Revenue, of Medical Segment 2012– 2013 ($Million)
Table 123. Ansell Ltd, Total Revenue, Sales By Region 2012– 2013 ($Million)
Table 124. Astrazeneca Net Revenue: 2011-2013 ($Million)
Table 125. Astrazeneca Net Revenue By Region: 2011-2012 ($Million)
Table 126. C. R. Bard Inc., Net Sales 2011– 2013 ($Million)
Table 127. C. R. Bard Inc., Revenue, By Segment 2013– 2011 ($Million)
Table 128. C.R.Bard Inc., Revenue, By Geography 2013– 2011 ($Million)
Table 129. C.R.Bard Inc., Revenue, R&D 2013– 2011 ($Million)
Table 130. Becton, Dickinson and Company; Net Revenue 2012- 2013 ($Million)
Table 131. Total Revenue; By Division 2012-2013($Million)
Table 132. Total Revenue; By Geography 2012-2013 ($Billion)
Table 133. Cantel Medical Corp. Net Revenue: 2011-2013 ($Million)
Table 134. Cantel Medical Corp. Net Sales By Segments 2011-2013 (%)
Table 135. Covidien, Total Revenue 2013– 2011 ($Million)
Table 136. Covidien, Total Revenue, By Segment 2013– 2011 ($Million)
Table 137. Covidien, Total Revenue, By Region 2013– 2011 ($Million)
Table 138. Covidien, Total Revenue, By R&D 2013– 2011 ($Million)
Table 139. Getinge Group Net Revenue: 2011-2013 ($Million)
Table 140. Getinge Infection Control Ab: Overview 2013 ($Million)
Table 141. Johnson & Johnson: Net Revenue 2011-2013 ($Million)
Table 142. Johnson & Johnson: Sales By Segment 2011-2013 ($Million)
Table 143. Johnson & Johnson: Sales By Region 2011-2013($Million)
Table 144. Johnson & Johnson: Sales of Business Segments In Geographic Areas 2011-2013 ($Million)
Table 145. Kimberly-Clark Net Revenue: 2011-2013 ($Million)
Table 146. Kimberly-Clark: Sales By Segment 2011-2013 ($Million)
Table 147. Kimberly-Clark: Sales By Region 2011-2013 ($Million)
Table 148. Merck & Co., INC Net Sales: 2011-2013 ($Billion)
Table 149. Merck & Co., INC Net Sales of Joint Venture Products: 2011-2013 ($Million)
Table 150. Pfizer Inc. Net Revenue: 2011-2013 ($Million)
Table 151. Pfizer Inc. Total Expenses: 2011-2013 ($Million)
Table 152. Pfizer Inc. Net Revenue By Segment: 2011-2013 ($Million)
Table 153. Pfizer Inc. Net Revenue By Regions: 2011-2013 ($Million)
Table 154. Roche Net Revenue, 2012-2013 ($Million)
Table 155. Roche Net Revenue: By Division, 2012-2013 ($Million)
Table 156. Siemens Ag: Total Revenue, 2012-2013 ($Million)
Table 157. Siemens Ag Revenue: By Divisions, 2011-2013 ($Million)
Table 158. Siemens Ag: Total Revenue By Region 2012-2013($Million)
Table 159. Supermax Corporation Berhad Net Revenue: 2011-2013 ($Million)
Table 160. Tso3 Net Revenue: 2011-2013 ($Million)
Table 161. 3m Net Income and R&D Expenditure of 3m, 2012-2013 ($Billion)


List of Figures:

Figure 1. Infection Prevention & Control Objective
Figure 2. Infection Prevention & Control Market – Classification
Figure 3. Infection Prevention & Control Market – Classification, By Type of Antimicrobial Drugs
Figure 4. Infection Prevention & Control Market, Classification, By Type of Accessories and Equipment
Figure 5. Infection Prevention & Control Market Oclassification, By End-User
Figure 6. Global IP&C Personal Protective Equipment Market, By Geography 2013 (%)
Figure 7. Global IP&C Market, By Geography, 2013 VS 2020 ($Billion)
Figure 8. Global IP&C Market – Market Share Analysis, By Key Players, 2013
Figure 9. IP&C, Patents By Key Players (2012-2014)
Figure 10. IP&C, Total Number of Patents (2010-2014)
Figure 11. IP&C, Total Number of Patents for Hand Sanitizers (2010-2014)
Figure 12. Model Depicting Triple Aim of Healthcare System
Figure 13. Value Chain Analysis of IP&C Market
Figure 14. Average Selling Price Analysis of Personal Protective Equipment Products - By Type, 2013-2020 ($)
Figure 15. Average Selling Price Analysis of Disinfectants, By Type, 2013-2020 ($)
Figure 16. Average Selling Price Analysis of Sterilization Equipment, By Type, 2013-2020 ($)
Figure 17. Average Selling Price Analysis of Autoclaves, By Type, 2013-2020 ($)
Figure 18. Average Selling Price Analysis of Anti-Microbial Drugs, By Type, 2013-2020 ($)
Figure 19. General Life Cycle of a Medical Products/Device
Figure 20. Life Cycle of a Medical Device
Figure 21. Global IP&C Anti Microbial Drugs Market, By Type of Anti-Microbial Infection, 2013 (%)
Figure 22. Global IP&C Accessories & Equipment Market, By Hai, 2013 (%)
Figure 23. Antibiotics Drug Pipeline (1980-2012)
Figure 24. Global IP&C Market, By Antimicrobial Drugs In 2013 (%)
Figure 25. Relationship Between Bacteria, Device & Host Towards Infection
Figure 26. Global IP&C Market, By Types of PPE, 2013 (%)
Figure 27. Global IP&C Market : By Types of Disinfectants In 2013 (%)
Figure 28. Global IP&C Market: By Types of Sterilization In 2013 (%)
Figure 29. Global IP&C Market: By Types of Autoclave In 2013 (%)
Figure 30. Global IP&C Market: By Accessories & Equipment’s End Users In 2013 (%)
Figure 31. Global IP&C Market, By Anti-Microbial Drugs End User’s 2013–2020 In 2013 (%)
Figure 32. Global IP&C Market: By Anti-Microbial Drug (a) and By Accessories & Equipments (B) In 2013 (%)
Figure 33. Infection and Prevention Control Market –By Type of Development (2012-2014)
Figure 34. Global Infection and Prevention Control Market – By Product Launches (2012-2014)
Figure 35. Global Infection and Prevention Control Market- Total Developments 2012 - 2014
Figure 36. Global Infection and Prevention Control Product Launches – By Key Players (2012 - 2014)
Figure 37. Sales By Division In 2013 (%)
Figure 38. Sales By Products In 2013 (%)
Figure 39. Sales By Regions In 2013 (%)
Figure 40. Getinge Group Net Sales: By Division, 2011-2013 (%)
Figure 41. Sales By Therapeutic Area In Pharmaceutical 2013 (%)
Figure 42. Sales By Major Franchise In Medical Devices and Diagnostics 2013 (%)
Figure 43. Sales By Major Franchise In Consumer 2013 (%)
Figure 44. Pharmaceutical Sales By Region In 2013 (%)
Figure 45. Pharmaceutical Sales By Therapeutic Area In 2013 (%)

Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports